Data Loading...
Cefepime HCl - Maxipime Flipbook PDF
Cefepime HCl - Maxipime
120 Views
104 Downloads
FLIP PDF 83.61KB
Cefepime HCl (Maxipime ®) The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgement. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Usual Diluents D5W, NS Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate] [0 to 2 grams] [50 ml] [30 min] Stability / Miscellaneous Label: Refrigerate. Stability data (below) DOSAGE AND ADMINISTRATION The recommended adult and pediatric dosages and routes of administration are outlined in the following table. MAXIPIME should be administered intravenously over approximately 30 minutes. Recommended Dosage Schedule for MAXIPIME in Patients with CrCL >60 mL/min. Duration Site and Type of Infection Dose Frequency (days) Adults *including cases associated with concurrent bacteremia **or until resolution of neutropenia. In patients whose fever resolves but who remain neutropenic for more than 7 days, the need for continued antimicrobial therapy should be re-evaluated frequently. ***IM route of administration is indicated only for mild to moderate, uncomplicated or complicated UTI’s due to E. coli when the IM route is considered to be a more appropriate route of drug administration. Moderate to Severe Pneumonia due to S. pneumoniae*, P. aeruginosa, K. pneumoniae, or 1-2 g IV q12h 10 Enterobacter species Empiric therapy for febrile neutropenic patients 2 g IV q8h 7** Mild to Moderate Uncomplicated or Complicated 0.5-1 g Urinary Tract Infections, including pyelonephritis, due q12h 7-10 IV/IM*** to E. coli, K. pneumoniae, or P. mirabilis* Severe Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis, due to E. coli or K. 2 g IV q12h 10 pneumoniae* Moderate to Severe Uncomplicated Skin and Skin 2 g IV q12h 10 Structure Infections due to S. aureus or S. pyogenes Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by E. coli, 2 g IV q12h 7-10 viridans group streptococci, P. aeruginosa, K. pneumoniae, Enterobacter species, or B. fragilis.
Site and Type of Infection
Dose
Frequency
Duration (days)
Adults Pediatric Patients (2 months up to 16 years) The maximum dose for pediatric patients should not exceed the recommended adult dose. The usual recommended dosage in pediatric patients up to 40 kg in weight for uncomplicated and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin structure infections, and pneumonia is 50 mg/kg/dose, administered q12h (50 mg/kg/dose, q8h for febrile neutropenic patients), for durations as given above. Impaired Hepatic Function No adjustment is necessary for patients with impaired hepatic function. Impaired Renal Function In patients with impaired renal function (creatinine clearance 60 mL/min), the dose of MAXIPIME should be adjusted to compensate for the slower rate of renal elimination. The recommended initial dose of MAXIPIME should be the same as in patients with normal renal function except in patients undergoing hemodialysis. Recommended Dosing Schedule for MAXIPIME in Adult Patients (Normal Renal Function, Renal Insufficiency, and Hemodialysis) Creatinine Recommended Maintenance Schedule Clearance (mL/min) *On hemodialysis days, cefepime should be administered following hemodialysis. Whenever possible, cefepime should be administered at the same time each day. >60 Normal recommended 500 mg q12h 1 g q12h 2 g q12h 2 g q8h dosing schedule 30-60 500 mg q24h 1 g q24h 2 g q24h 2 g q12h 11-29 500 mg q24h 500 mg q24h 1 g q24h 2 g q24h